
IART Stock Forecast & Price Target
IART Analyst Ratings
Bulls say
Integra Lifesciences Holdings Corp has demonstrated a strong performance in its Neurosurgery portfolio, with management highlighting double-digit growth in Georgian and Mayfield capital equipment, indicating healthy demand in this segment. The Instruments subsegment reported revenue of $51.0 million during the quarter, reflecting a robust 15.1% organic growth compared to the previous year. Despite a slight decline in the Wound Reconstruction segment, the overall positive trends in key product categories such as DUraSorb, MicroMatrix, and Cytal reinforce a favorable outlook for the company's financials.
Bears say
Integra Lifesciences Holdings Corp is forecasting an adjusted EPS of $0.40-$0.45, which reflects a significant year-over-year decline of approximately 23%, exacerbated by a $0.04 negative impact from tariffs. Additionally, the company reported that international sales are down by low double digits compared to the previous year, although this decline fell within their expectations as they work to optimize the Integra Skin product line. Furthermore, a gross margin of 62.2% indicates a decrease of around 220 basis points year-over-year, primarily attributed to manufacturing variances and supply chain inefficiencies anticipated for 2024.
This aggregate rating is based on analysts' research of Integra LifeSciences Holdings and is not a guaranteed prediction by Public.com or investment advice.
IART Analyst Forecast & Price Prediction
Start investing in IART
Order type
Buy in
Order amount
Est. shares
0 shares